蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 3877|回复: 10
收起左侧

[申报注册] 印度PAN DRUG的FDA警告信(节译)

[复制链接]
药徒
发表于 2016-9-7 08:45:08 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
看完缺陷,深深感觉GMP检查报告写出的问题没有最奇葩,只有更奇葩。
官网链接http://www.fda.gov/ICECI/Enforce ... /2016/ucm518540.htm



Warning Letter 320-16-29
Via UPS
Return Receipt Requested
August 25, 2016
Mr. Kamal Pandya
Managing Director and Chairman
Pan Drugs Limited
192 G I D C Makarpura Industrial Estate
M I Estate, Vadodara 390001
India
Dear Mr. Pandya:
The U.S. Food and Drug Administration (FDA) inspected yourpharmaceutical manufacturing facility, Pan Drugs Limited, 192 G I D C MakarpuraIndustrial Estate, M I Estate, Vadodara, from November 30 to December 3, 2015.
  美国FDA于2015年11月30日至12月3日检查了你们印度的公司。
This warning letter reviews significant violations of current goodmanufacturing practice (CGMP) for finished pharmaceuticals. See 21 CFR, parts210 and 211.
  本警告信总结了制剂严重违反CGMP的问题。参见21 CFR, parts 210和 211
Because your methods, facilities, or controls for manufacturing,processing, packing, or holding do not conform to CGMP, your drug products areadulterated within the meaning of section 501(a)(2)(B) of the Federal Food,Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).
鉴于你们生产、加工、包装和保存的方法、设施或控制不符合CGMP要求,你们的原料药根据FDCA501(a)(2)(B)和21 U.S.C.351(a)(2)(B)规定被判定为掺假药品。
We reviewed your firm’s December 17, 2015, response in detail.
  我们详细审核了贵公司于2015年12月17日发出的回复。
During our inspection, our investigators observed specific violationsincluding, but not limited to, the following.
  我们的检查人员发现的具体违规情况包括但不仅限于以下:
1.    Your firm failed to establish an adequate qualitycontrol unit with the responsibility and authority to approve or reject allcomponents, drug product containers, closures, in-process materials, packagingmaterial, labeling, and drug products (21 CFR 211.22(a)).
贵公司未能建立足够的质量控制部门,具备职责和权力来批准或拒收所有组份、药品容器、密闭器、中控物料、包装材料、标签和药品(21 CFR 211.22(a))。
Your firm’s quality unit allowed the use of adulterated (b)(4) USPAPI, dated May 25–31, 2015, manufactured at the Pan Drugs Ltd. Nandesari facility.The Pan Drugs Ltd. Nandesari facility was placed on FDA import alert 66-40 onMay 5, 2015, for egregious CGMP deviations. Your firm used this API for themanufacture of (b)(4), which were then shipped to the U.S. market fromOctober 7 to November 23, 2015.
贵公司的质量部门允许使用掺假的某USP原料药,日期为2015年5月25-31日,在PAN DRUG的NANDESARI工厂生产的。由于严重CGMP违规,PAN DRUG NANDESARI工厂已于2015年5月5日被FDA发布进口禁令。贵公司使用了此原料药用于某制剂的生产,然后在2015年10月7日至11月23日发往美国销售。
Additionally, your quality unit approved certificates of analysis (COA)for (b)(4) and (b)(4) API, as well as finished products, prior toconducting all quality control and release testing. Your production managerfalsified the documents by signing and dating the “Prepared By” and “CheckedBy” sections of the COA.
另外,你们的质量部门在实施所有质量控制和放行检测之前,就批准了某原料药的检验报告书(COA),以及制剂的COA。贵司生产经理在COA的“制表人”和“审核人”处签字日期从而伪造了文件。
Furthermore, your quality unit failed to identify data integrity issues in11 batch production records reviewed by our investigator. Your productionmanager admitted that he falsified the signatures of other employees in the“Prepared By,” “Reviewed By,” “Approved By,” and “Authorized By” sections.
还有,贵司质量部门未能在我们调查人员审核的11批生产记录中识别出数据完整性问题。贵司生产经理承认他在“制表人”、“审核人”、“批准人”和“授权人”处伪造了其它员工的签名。
According to your response, you recognized that these practices were notadequate. You intended to implement a signature list and revise your SOPs toaddress these failures. However, these actions do not address the quality unitfailures observed.
根据贵司的回复,你们认识到了这些做法都是不好的。你们将实施签名清单,修改你们的SOP来管理此问题。但是,这些措施并没有涉及到发现的质量部门问题。
2.    Your firm failed to maintain the buildings used inthe manufacture, processing, packing, or holding of a drug product in a cleanand sanitary condition and to keep them free of infestation by rodents, birds,insects, and other vermin (21 CFR 211.56(a)).
贵公司未能维护药品生产、加工、包装和存贮所用的建筑使其保持洁净和卫生状态,维护其不受啮齿动物、鸟儿、昆虫和其它害虫害兽的侵入(21 CFR 211.56(a))
For example, our investigators observed mold-like substances on the wallsof your drug processing area, and accumulations of (b)(4) powderthroughout your facility.
例如,我们的调查人员发现在你们药品加工区域的墙面上有霉菌样物质,在整个设施中都看到累积的某粉尘。
Our investigators also observed gaps and holes in the walls of yourfacility around piping and air ducts. These gaps and holes were open to thesurrounding environment and allowed pests to enter your facility. During the inspection,we observed a lizard exiting one of the holes, and evidence of other pestactivity. For example, our investigators observed what appeared to be rodentdroppings within three feet of (b)(4) bags purported to hold (b)(4)drug product.
我们的调查人员还发现你们墙上工厂里管道和排气管留有间隙和洞。这些间隙和洞向周围环境敞开,使得虫鼠可以进入你们工厂。在检查期间,我们发现有一只蜥蜴从洞里出去,还有其它虫害活动的证据。例如,我们调查人员发现用于存贮某药品的某袋子3英尺内有一些啮齿动物的粪便样的东西。
3.    Your firm failed to clean, maintain, and, as appropriatefor the nature of the drug, sanitize and/or sterilize equipment and utensils atappropriate intervals to prevent malfunctions or contamination that would alterthe safety, identity, strength, quality, or purity of the drug product beyondthe official or other established requirements (21 CFR 211.67(a)).
贵公司未能根据药品的特性要求按适当的时间间隔清洁、维护和消毒和/或灭菌设备和工器具,以防止发生故障或污染,从而改变药品的安全性、鉴别、剂量、质量或纯度使其不符合官方或其它既定要求 (21 CFR 211.67(a))
For example, our investigators observed rust, dirt, and lubrication leakson and around your shared drug manufacturing equipment. Your processing (b)(4)for the production of (b)(4) and (b)(4) had non-food-gradeoil on and around the equipment. We also observed black particles in the (b)(4)used in manufacturing drug products. You told our investigator that your firmhad no cleaning procedure for the equipment or facility.
例如,我们调查人员发现你们共用的药品生产设备上及其周围有生锈、污渍和润滑油泄漏。你们生产某产品的设备使用了非食用级油品。我们还发现在药品生产所用的某设备上有黑色颗粒物。你们告诉我们调查人员贵司没有设备或设施的清洁程序。
Your equipment was observed to be in poor operating condition. Forexample, we observed a warped lid on your “(b)(4)” that prevented properclosure.  
贵司设备处于不良运行状态。例如,我们发现某设备上有一个盖子变形了,无法关闭。
In response to this letter, provide details of the plan you stated youwill develop for facility upgrades and corrections, including photographicevidence that demonstrates that the entire facility meets CGMP requirements.Your response should also include your plan to ensure your facility andequipment will be proactively maintained in such a way that your product iscontinually manufactured under CGMP conditions.
在回复此函时,请提供详细的计划,说明你们将如何对设施进行升级和改造,包括图片证据证明整个设施符合CGMP要求。你们的回复还应包括你们确保你们会对你们的设施和设备进行主动维护的计划,保证你们的药品持续在CGMP条件下生产。
4.    Your firm failed to exercise appropriate controls overcomputer or related systems to assure that only authorized personnel institutechanges in master production and control records, or other records (21 CFR211.68(b)).
贵公司未能对计算机或相关系统进行适当的控制,以确保只有经过授权的人员才能修改主生产和检验记录,以及其它记录(21 CFR 211.68(b))
For example, the computer in your quality unit area did not have controlsto restrict access and prevent unauthorized changes to data files and folders.All employees had access to your Annual Product Review (APR) spreadsheet. Thedesktop computer containing the APR was not locked.
例如,你们质量部门区域的计算机并没有控制来限制进入,防止未经授权地修改数据文件和文件夹。所有员工都可以登录你们的年度质量回顾(APR)工作表。保存APR的台式计算机没有锁定。
In your response, you committed to “reassessing the GMP” requirements forcomputer-based systems; you stated the systems would be “evaluated, checked andvalidated.” You did not include a timeline or specify a plan to review releasedbatches and determine the impact of the deficiency.
在你们的回复中,你们承诺会“重新评估GMP”对基于计算机系统的要求,你们声称系统会被“评估、检查和验证”。你们没有包括一份时间表,也没有说明你们审核已放行批次确定缺陷造成影响的计划。
Data Integrity Remediation 数据完整性问题弥补
Your quality system does not adequately ensure the accuracy and integrityof data to support the safety, effectiveness, and quality of the drugs youmanufacture. We acknowledge that you are using a consultant to audit youroperation and assist in meeting FDA requirements. In response to this letter,provide the following.
你们的质量体系不能充分确保数据的准确性和完整性,无法支持你们生产的药品的安全性、有效性和质量。我们知道你们聘请了顾问来审计你们的操作,协助符合FDA要求。在回复此函时,提供以下资料:
A.  A comprehensive investigation into the extent of the inaccuraciesin data records and reporting. Your investigation should include: 一份对数据记录和报告不准确性程度的全面调查。你们的调查应包括:
  • A detailed     investigation protocol and methodology; a summary of all laboratories,     manufacturing operations, and systems to be covered by the assessment; and     a justification for any part of your operation that you propose to     exclude.
  • 详细的调查方案和方法学;对评估所覆盖的所有化验室、生产操作和系统的总结,以及对你们意在排除的操作中所有部分的论证。
  • Interviews of     current and former employees to identify the nature, scope, and root cause     of data inaccuracies. We recommend that these interviews be conducted by a     qualified third party.
  • 与现有的和已离职的员工进行面谈,找出数据不准确的表现、范围、根本原因。我们建议这些面谈由一个有资质的第三方来实施。
  • An assessment of     the extent of data integrity deficiencies at your facility. Identify     omissions, alterations, deletions, record destruction, non-contemporaneous     record completion, and other deficiencies. Describe all parts of your     facility’s operations in which you discovered data integrity lapses.
  • 你们工厂数据完整性缺陷的程度的评估。识别出省略、修改、删除、记录销毁、不同步记录填写和其它缺陷。描述你们工厂操作中发现数据完整性问题的所有部分。
  • A comprehensive     retrospective evaluation of the nature of the testing and manufacturing     data integrity deficiencies. We recommend that a qualified third party     with specific expertise in the area where potential batches were     identified evaluate all data integrity lapses.
  • 一份对数据完整性缺陷状况的全面回顾性评估。我们建议由一个有资质的第三方里具有该领域专业水平的专家评估所有数据完整性问题。
B.  A current risk assessment of the potential effects of theobserved failures on the quality of your drugs. Your assessment should include analysesof the risks to patients caused by the release of drugs affected by a lapseof data integrity, and risks posed by ongoing operations.
对你们药品质量中所发现的不合格情况的潜在影响的当前风险评估。你们的评估应包括由于受到数据完整性问题影响的药品放行导致的患者风险的分析,以及持续运营所具有的风险。
C.  A management strategy for your firm that includes the details ofyour global corrective action and preventive action plan. Your strategy shouldinclude:
你们公司的管理策略,包括你们全球CAPA计划详细情况。你们的策略应包括:
  • A detailed     corrective action plan that describes how you intend to ensure the     reliability and completeness of all of the data you generate, including     analytical data, manufacturing records, and all data submitted to FDA.
  • 详细的CA计划,描述你们如何确保你们生成的所有数据的可靠性和完整性,包括分析数据、生产记录和所有提交给FDA的数据。
  • A comprehensive     description of the root causes of your data integrity lapses, including     evidence that the scope and depth of the current action plan is     commensurate with the findings of the investigation and risk assessment.     Indicate whether individuals responsible for data integrity lapses remain     able to influence CGMP-related data at your firm.
  • 一份完整的描述你们数据完整性问题的根本原因的描述,包括认定当前行动计划的范围和深度与调查和风险评估发现相称的证据。说明是否对数据完整性问题承担责任的个人仍有能力对你公司对CGMP相关或药物应用数据产生影响。
  • Interim measures     describing the actions you have taken or will take to protect patients and     to ensure the quality of your drugs, such as notifying your customers,     recalling product, conducting additional testing, adding lots to your     stability programs to assure stability, drug application actions, and     enhanced complaint monitoring.
  • 临时措施,描述你们已采取的行动,或即将采取用以保护患者确保你们药品质量的努力,例如通知你们的客户、召回产品、实施额外测试、向稳定性试验计划中增加批次以确保稳定性、药品申报行动以及加强投诉监测。
  • Long-term measures     describing any remediation efforts and enhancements to procedures,     processes, methods, controls, systems, management oversight, and human     resources (e.g., training, staffing improvements) designed to ensure the     integrity of your company’s data.
  • 长期措施,描述所有对程序、工艺、方法、控制、系统、管理监管和人力资源(例如,培训、员工提升)的弥补措施和改善措施,以确保你们公司数据的完整性。
  • A status report for     any of the above activities already underway or completed.
  • 对上述活动已开展或已经完成的状态报告。
Access to Information during Inspection 检查期间信息获取情况
Your firm attempted to delay the start of the inspection, and some recordswe requested during the inspection were not provided.
贵公司试图拖延检查开始,在检查期间我们索取的一些记录并没有提供。
On November 30, 2015, our investigator observed your warehouse supervisortearing out pages from your firm’s annual report and placing the pages into hispocket. Eventually, the supervisor provided the pages to our investigator.
在2015年11月30日,我们调查人员发现你们的仓库主管撕毁你们公司年度报告的几页,并放进了自己的口袋。最后,主管给我们的调查人员提供了那几页文件。
On December 1, 2015, our investigator requested printed chromatograms fromyou HPLC and GC. You failed to provide them.
在2015年12月1日,我们调查人员索取你们HPLC和GC里打印出的色谱图。你们没有提供。
When an owner, operator, or agent delays, denies, limits, or refuses aninspection, the drugs may be adulterated under section 501(j) of the FD&CAct. We recommend that you review FDA’s guidance for industry, Circumstancesthat Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM360484.pdf
当所有者、运营商或代理延误、否决、限制或拒绝检查,则根据FDCA 501(j)的规定将其生产的药品判定为掺假药品。我们建议你们查看FDA行业指南“延误、否决、限制或拒绝药品检查的情形”。
Conclusion
Violations cited in this letter are not intended as an all-inclusive list.You are responsible for investigating these violations, for determining thecauses, for preventing their recurrence, and for preventing other violations.
FDA placed your firm on Import Alert 66-40 on December 8, 2015.
Until you correct all violations completely and we confirm your compliancewith CGMP, FDA may withhold approval of any new applications or supplementslisting your firm as a drug product manufacturer.
Failure to correct these violations may also result in FDA continuing torefuse admission of articles manufactured at Pan Drugs Limited, 192 G I D CMakarpura Industrial Estate, M I Estate, Vadodara into the United States undersection 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Under the same authority,articles may be subject to refusal of admission, in that the methods andcontrols used in their manufacture do not appear to conform to CGMP within themeaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).
After you receive this letter, respond to this office in writing within 15working days. Specify what you have done since our inspection to correct yourviolations and to prevent their recurrence. If you cannot complete correctiveactions within 15 working days, state your completion date and reasons fordelay.
Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.govor mail your reply to:
Carla Norris
Compliance Officer
U.S. Food and Drug Administration
White Oak Building 51, Room 4359
10903 New Hampshire Avenue
Silver Spring, MD 20993
USA
Please identify your response with FEI 3010532174.
Sincerely,
/S/
Francis Godwin
Acting Director
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research



回复

使用道具 举报

药士
发表于 2016-9-7 08:48:00 | 显示全部楼层
贵公司的质量部门允许使用掺假的某USP原料药,日期为2015年5月25-31日,在PAN DRUG的NANDESARI工厂生产的。由于严重CGMP违规,PAN DRUG NANDESARI工厂已于2015年5月5日被FDA发布进口禁令。贵公司使用了此原料药用于某制剂的生产,然后在2015年10月7日至11月23日发往美国销售。——这条也是NB啊,FDA要把自己的权威亮出来,既然想进美国市场就要按他们的规矩办事。
回复

使用道具 举报

药士
发表于 2016-9-7 08:50:53 | 显示全部楼层
另外,你们的质量部门在实施所有质量控制和放行检测之前,就批准了某原料药的检验报告书(COA),以及制剂的COA。贵司生产经理在COA的“制表人”和“审核人”处签字日期从而伪造了文件。——这个也是厉害啊,生产经理在COA上签字,当质量部人死光了吧。另外,提前搞空白报告单这种在一些小厂签字的负责人出差一段时候的情况下才会出现这种提前伪造签字的情况。
回复

使用道具 举报

药士
发表于 2016-9-7 08:53:20 | 显示全部楼层
在检查期间,我们发现有一只蜥蜴从洞里出去,还有其它虫害活动的证据。例如,我们调查人员发现用于存贮某药品的某袋子3英尺内有一些啮齿动物的粪便样的东西。——很好,点个赞,很多企业没有做到实处,以为自己有防虫防鼠的文件了,管理也马马虎虎了,应该不至于运气这么差就被点出缺陷吧。
回复

使用道具 举报

药士
发表于 2016-9-7 08:56:12 | 显示全部楼层
我们调查人员发现你们共用的药品生产设备上及其周围有生锈、污渍和润滑油泄漏。你们生产某产品的设备使用了非食用级油品。我们还发现在药品生产所用的某设备上有黑色颗粒物。你们告诉我们调查人员贵司没有设备或设施的清洁程序。——我估计这是家化工厂吧,TMD怎么就搞起原料药、制剂来了,看样子印度这个国家真行啊,喝动物的尿、喂老鼠当神物,大家买点印度神油吧
回复

使用道具 举报

药士
发表于 2016-9-7 08:58:26 | 显示全部楼层
与现有的和已离职的员工进行面谈,找出数据不准确的表现、范围、根本原因。我们建议这些面谈由一个有资质的第三方来实施。这个调查好全面,全中国药企都做不到吧。
回复

使用道具 举报

发表于 2016-9-7 09:20:34 | 显示全部楼层
当面将记录撕毁隐藏,印度佬怎么想的,很奇怪他们怎么成为世界药房?印度要不要也通过类似中国这种一致性评价才能进入欧美市场啊?
回复

使用道具 举报

发表于 2016-9-7 09:20:55 | 显示全部楼层
zysx01234 发表于 2016-9-7 08:56
我们调查人员发现你们共用的药品生产设备上及其周围有生锈、污渍和润滑油泄漏。你们生产某产品的设备使用了 ...

印度神油都不敢放心用了

点评

可能就是几种动物的尿配起来的  详情 回复 发表于 2016-9-7 09:27
回复

使用道具 举报

药士
发表于 2016-9-7 09:27:35 | 显示全部楼层
couragezhao 发表于 2016-9-7 09:20
印度神油都不敢放心用了

可能就是几种动物的尿配起来的
回复

使用道具 举报

药士
发表于 2016-9-7 09:30:09 | 显示全部楼层
贵公司试图拖延检查开始,在检查期间我们索取的一些记录并没有提供。
在2015年11月30日,我们调查人员发现你们的仓库主管撕毁你们公司年度报告的几页,并放进了自己的口袋。最后,主管给我们的调查人员提供了那几页文件。
在2015年12月1日,我们调查人员索取你们HPLC和GC里打印出的色谱图。你们没有提供
当所有者、运营商或代理延误、否决、限制或拒绝检查,则根据FDCA 501(j)的规定将其生产的药品判定为掺假药品。我们建议你们查看FDA行业指南“延误、否决、限制或拒绝药品检查的情形”。——果然是满满的警告
回复

使用道具 举报

大师
发表于 2016-9-7 12:52:59 | 显示全部楼层
问题不少,看得出该企业日常管理松散
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( (京)-非经营性-2014-0058 京ICP证150354号 京ICP备14042168号-1 )

GMT+8, 2024-3-28 18:23

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表